After years of disappointing ALS clinical trial results, this year's Sheila Essey Award recipient for significant contributions in ALS research is shifting to prevention.
The lecanemab open-label extension trial for AD showed no new safety signals, but the placebo roll-over group failed to show the gains seen in the experimental arm.